Simulations Plus Realizes Early Success with its Concierge Program

Investments made to accelerate adoption of new approaches through strategic partnerships with organizations globally

LANCASTER, Calif.–(BUSINESS WIRE)–Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation software and services for pharmaceutical safety and efficacy, recently invested in the creation of their Concierge Program, facilitating value-added strategic partnerships with customers through alliance management.

The Concierge Program is designed to provide customer support through true partnership and planning. It includes regular meetings and communication, detailed understanding of customers’ future needs, key performance indicators to measure progress, and a central point of contact to provide guidance and answers along the way.

To date, multiple large pharma, contract research organizations (CROs), and regulatory partners have enrolled in the Concierge Program. These customers have already experienced the benefits of this program and have accelerated their development programs, aligned with the strategic vision of Simulations Plus. Examples of recent successes include bespoke training programs for regulatory scientists in Canada, Europe, and South America, customized software development for new research programs, and escalated consulting support to meet filing deadlines.

“I truly believe that the key to success for our customers hinges on our ability to understand their needs now and into the future,” said Nate Musser, Director of Alliance Management. “By engaging regularly and transparently, we can support our partners in making nimble research decisions while aligning with their goals. That kind of partnership and forward thinking makes a world of difference in bringing timely solutions to the people who need them.”

About Simulations Plus

Serving clients worldwide for 25 years, Simulations Plus is a leading provider in the biosimulation market providing software and consulting services supporting drug discovery, development, research, and regulatory submissions. We offer solutions that bridge machine learning, physiologically based pharmacokinetics, quantitative systems pharmacology/toxicology, and population PK/PD modeling approaches. Our technology is licensed and applied by major pharmaceutical, biotechnology, and regulatory agencies worldwide. For more information, visit our website at Follow us on LinkedIn | Twitter | YouTube.

Environmental, Social, and Governance (ESG)

We focus our Environmental, Social, and Governance (ESG) efforts where we can have the most positive impact. To learn more about our latest initiatives and priorities, please visit our website to read our ESG Report.

Safe Harbor Statement Under the Private Securities Litigation Reform Act of 1995 – With the exception of historical information, the matters discussed in this press release are forward-looking statements that involve a number of risks and uncertainties. Words like “believe,” “expect” and “anticipate” mean that these are our best estimates as of this writing, but that there can be no assurances that expected or anticipated results or events will actually take place, so our actual future results could differ significantly from those statements. Factors that could cause or contribute to such differences include, but are not limited to: our ability to maintain our competitive advantages, acceptance of new software and improved versions of our existing software by our customers, the general economics of the pharmaceutical industry, our ability to finance growth, our ability to continue to attract and retain highly qualified technical staff, our ability to identify and close acquisitions on terms favorable to the Company, and a sustainable market. Further information on our risk factors is contained in our quarterly and annual reports and filed with the U.S. Securities and Exchange Commission.


Simulations Plus Investor Relations
Ms. Renee Bouche


Hayden IR
Mr. Brian Siegel


error: Content is protected !!